Dr. Frank A. Cordasco

speaker

137 appearances 1 recordings 1 series first heard Feb 2026 last heard 3 Feb

Dr. Frank A. Cordasco’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

Becker’s Healthcare -- Spine and Orthopedic Podcast · The Future of Sports Medicine and Orthopedics With Dr. Frank A. Cordasco · 3 Feb 2026 podcast

utilize these on a daily basis in our offices and sometimes in our operating rooms.

So, biologics I think of in three basic ways, blood-borne, bone marrow derived and adipose tissue.

And so, for example, if I'm treating a younger athlete who has early osteoarthritis that is not a surgical problem, I might utilize a biologic to enhance

pain relief and symptom relief.

And I think I'll before getting into details, I'll sort of qualify this by saying we wish we had more data than we do.

And I think that's going to explode with the help of AI over the next two years.

So historically, we believe that these products can help and we have patient data that suggests that it will help, but we don't necessarily have the numbers for evidence based

assessment that would allow healthcare delivery systems to feel comfortable reimbursing for it.

So as you know now, most of these techniques are not reimbursable upon, rather, by healthcare delivery systems.

So the onus is on the patient

to sort of establish these resource allocations, which is hard.

So as a surgeon, as a clinical practitioner, it's hard for me to recommend a technology that requires the patient to expend a resource allocation.

Having said that, there is data available for

for example, PRP to manage the use of these techniques for early osteoarthritis.

So there are lots of systematic reviews and meta-analyses that will allow us to definitively say PRP is better than, for example, VSCO supplementation for the management of early osteoarthritis.

And I think that's an easy lift for most of us because the data is there.

So I mentioned the management of early OA in young athletes.

There are other aspects.

And a lot of this, Carly, honestly, is joint and disease specific.

So we know, for example, and we've published on this at HSS, that some joints are more responsive and some tendon groups are more responsive to the application of PRP

Showing 101–120 of 137 · page 6 of 7